找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Cancer; Robert H. Bradbury Book 2007 Springer-Verlag Berlin Heidelberg 2007 Cancer.Chemotherapy.Tumour.angiogenesis.biology.chemistry.medi

[复制链接]
楼主: 归纳
发表于 2025-3-25 06:05:37 | 显示全部楼层
Roles of Microglia in Spinal Cord Injuryole in controlling cell growth, proliferationand survival. Whatever the mechanism, the prevalence of PI3K/PKB signaling abnormalities in human cancercells has suggested the potential use of PI3K/PKB pathway modulators as novel targeted therapeutic agents.Although often non-selective for the intended
发表于 2025-3-25 10:10:22 | 显示全部楼层
发表于 2025-3-25 11:39:07 | 显示全部楼层
Kenzo Uchida,Masaya Nakamura,Yoshiaki Toyamaical background of HDACs and their link to cancer andcancer treatment. The body of the work consists of a categorized and chronological medicinal chemistryoverview. This part describes key medicinal chemistry contributions ranging from the very early HDAC inhibitorsto compounds currently in the clin
发表于 2025-3-25 15:56:10 | 显示全部楼层
https://doi.org/10.1007/978-981-99-7269-2 of the molecular mechanisms underlyingthe angiogenesis process have led to the discovery of a variety of pharmaceutical agents withantiangiogenic activity. The potential application of these angiogenesis inhibitors is currentlyunder intense clinical investigation. Decades of investigation suggest t
发表于 2025-3-25 20:32:50 | 显示全部楼层
发表于 2025-3-26 00:15:31 | 显示全部楼层
发表于 2025-3-26 07:44:06 | 显示全部楼层
发表于 2025-3-26 12:03:03 | 显示全部楼层
发表于 2025-3-26 15:35:59 | 显示全部楼层
Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK,significant number of kinase inhibitors have recentlyentered clinical practice for the treatment of a variety of cancers and many others are in advancedstages of clinical research. Among these are several promising agents that act in the pathway that initiateswith the growth factor receptors EGFR/Er
发表于 2025-3-26 18:54:31 | 显示全部楼层
Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms, and Progress inl-molecule inhibitors that could be developedas oral therapeutics. There are now several farnesyl protein inhibitors (FTIs) in various phases of clinicaldevelopment and at least two compounds have entered phase III. The published data suggest some disappointingactivity in the major solid tumors, wit
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-7-2 18:42
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表